ADMA Biologics Granted U.S. Patent for Treating Respiratory Infections

ADMA Biologics (NASDAQ:ADMA) announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 9,969,793 covering methods of treating respiratory infections.

As quoted in the press release:

The newly issued patent encompasses methods of treating upper and lower respiratory infections, including those caused by Respiratory Syncytial Virus (“RSV”), other viruses, as well as bacteria utilizing ADMA’s investigational drug RI-002 that contains elevated, neutralizing antibody titers to RSV as well as elevated antibody titers to other respiratory pathogens, such as influenza virus, coronavirus, parainfluenza virus, and metapneumovirus. The term of the issued patent extends to January 2035.

“The addition of this patent to ADMA’s immunoglobulin portfolio provides unique coverage for the therapeutic treatment of respiratory infections using our investigational drug RI-002,” stated Adam Grossman, President and CEO of ADMA.

Click here to read the full press release.